Kiora Pharmaceuticals (NASDAQ:KPRX) Earns Buy Rating from HC Wainwright

Kiora Pharmaceuticals (NASDAQ:KPRXGet Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $10.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 190.70% from the company’s previous close.

Kiora Pharmaceuticals Stock Down 5.0 %

Shares of Kiora Pharmaceuticals stock opened at $3.44 on Tuesday. The business has a fifty day simple moving average of $3.53 and a two-hundred day simple moving average of $4.28. Kiora Pharmaceuticals has a 1 year low of $3.00 and a 1 year high of $8.98.

Kiora Pharmaceuticals (NASDAQ:KPRXGet Free Report) last posted its earnings results on Friday, November 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.09. Sell-side analysts predict that Kiora Pharmaceuticals will post 1.17 EPS for the current year.

Hedge Funds Weigh In On Kiora Pharmaceuticals

A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC acquired a new stake in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRXFree Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals makes up about 0.8% of Stonepine Capital Management LLC’s holdings, making the stock its 16th biggest position. Stonepine Capital Management LLC owned 6.86% of Kiora Pharmaceuticals at the end of the most recent reporting period. 76.97% of the stock is currently owned by institutional investors.

About Kiora Pharmaceuticals

(Get Free Report)

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.

Recommended Stories

Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.